RenovoRx logo

RenovoRxNASDAQ: RNXT

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

26 August 2021

Next earnings report:

16 August 2024

Last dividends:

N/A

Next dividends:

N/A
$26.83 M
-80%vs. 3y high
27%vs. sector
-vs. 3y high
-vs. sector
-99%vs. 3y high
96%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Tue, 02 Jul 2024 23:37:11 GMT
$1.12-$0.06(-5.08%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

RNXT Latest News

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial
globenewswire.com26 June 2024 Sentiment: -

Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
globenewswire.com10 June 2024 Sentiment: -

New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology New role highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology

RenovoRx CEO Issues Update Letter to Shareholders
businesswire.com30 May 2024 Sentiment: POSITIVE

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today provided a letter to shareholders from Chief Executive Officer, Shaun Bagai. Dear Fellow RenovoRx Shareholders, The first quarter of 2024 marked a significant period in our company's evolution, and we have set the stage for significant milestones in the foreseeable.

RNXT Stock Earnings: RenovoRx Meets EPS for Q4 2023
InvestorPlace08 April 2024 Sentiment: NEGATIVE

RenovoRx (NASDAQ: RNXT ) just reported results for the fourth quarter of 2023. RenovoRx reported earnings per share of -30 cents.

What type of business is RenovoRx?

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

What sector is RenovoRx in?

RenovoRx is in the Healthcare sector

What industry is RenovoRx in?

RenovoRx is in the Biotechnology industry

What country is RenovoRx from?

RenovoRx is headquartered in United States

When did RenovoRx go public?

RenovoRx initial public offering (IPO) was on 26 August 2021

What is RenovoRx website?

https://renovorx.com

Is RenovoRx in the S&P 500?

No, RenovoRx is not included in the S&P 500 index

Is RenovoRx in the NASDAQ 100?

No, RenovoRx is not included in the NASDAQ 100 index

Is RenovoRx in the Dow Jones?

No, RenovoRx is not included in the Dow Jones index

When does RenovoRx report earnings?

The next expected earnings date for RenovoRx is 16 August 2024